Asia Pacific Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging)

Asia Pacific Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging), and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian)

The biopharmaceutical contract manufacturing market in Asia-Pacific is expected to grow from US$ 2,973.92 million in 2021 to US$ 5,462.23 million by 2028; it is estimated to register a CAGR of 9.1% from 2021 to 2028.Asian countries are emerging as attractive outsourcing locations for biopharmaceutical industries. Low manufacturing and operating costs in China and India are the key factors that will drive the growth of the biopharmaceutical contract manufacturing market in the region. Recent growth in the biopharmaceutical industry in these countries indicates a positive outlook for this market. Moreover, the growing domestic market and its pipelines are opening new avenues for biopharmaceutical contract manufacturers in Asia-Pacific. China’s pipelines have shown rapid growth in recent years. According to the International Society for Pharmaceutical Engineering, in 2016, the China Food and Drug Administration (CFDA) registered ~200 new biological pharmaceuticals entering clinical trials. Moreover, many CMOs are expanding their manufacturing capabilities to meet the growing demand, boosting the biopharmaceutical contract manufacturing market growth. For instance, in January 2020, STA Pharmaceutical Co. Ltd. (a subsidiary of Wu Xi App Tec) opened a new large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in China. Additionally, Bushu Pharmaceuticals expanded its contract-manufacturing pact with Amgen across Asia, which includes countries such as China, Taiwan, and South Korea. The CMO is expected to double its volume of Amgen products and will be responsible for assembly, labeling, packaging, and inspection of drugs, such as Repatha, Evenity, Prolia, and Xgeva. Similarly, in 2021, Astra Zeneca contracted with JCR Pharmaceuticals in Japan to produce its COVID-19 vaccine solution. Further, JCR announced the decision to construct a new plant. These developments signify a significant emerging opportunity for pharmaceutical & biopharmaceutical companies in Asia-Pacific.

Asia-Pacific Biopharmaceutical Contract Manufacturing Market Revenue and Forecast to 2028 (US$ Million)

Asia-Pacific Biopharmaceutical Contract Manufacturing Market Segmentation

Asia-Pacific Biopharmaceutical Contract Manufacturing Market – By Product

Biologics Monoclonal Antibodies Recombinant Proteins Vaccines Others Biosimilar

Asia-Pacific Biopharmaceutical Contract Manufacturing Market – By Service

Process Development Downstream Processing Upstream Processing Fill and Finish Operation Analytical and QC Studies Packaging

Asia-Pacific Biopharmaceutical Contract Manufacturing Market – By Source

Mammalian Microbial-Based Biologics/ Non-Mammalian

Asia-Pacific Biopharmaceutical Contract Manufacturing Market– By Country

Japan China India South Korea Australia The Rest of Asia-Pacific Asia-Pacific Biopharmaceutical Contract Manufacturing Market-Companies Mentioned

Abb Vie Inc.Ajinomoto Co. Inc Boehringer Ingelheim International Gmb HGeneral Electric Company Lonza MERCK KGAASamsung Biologics THERMO FISHER SCIENTIFIC INCWUXI BIOLOGICS

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia-Pacific Biopharmaceutical Contract Manufacturing Market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia-Pacific Biopharmaceutical Contract Manufacturing Market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia-Pacific market trends and outlook coupled with the factors driving the Biopharmaceutical Contract Manufacturing Market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution